IPOs
Iambic attracts Wall Street attention; clinical proof remains the test
IAM’s supplied chart shows $15.30 and +14.35%. Analyst coverage adds attention, but AI-drug discovery still has to deliver clinical evidence.
Read the story
IAM’s supplied chart shows $15.30 and +14.35%. Analyst coverage adds attention, but AI-drug discovery still has to deliver clinical evidence.
Read the story